In the new arms, patients with certain biomarker-defined tumors will receive either an HLA-G targeted antibody, chemo, and Erbitux, or just chemo and Erbitux.
Eisai has argued that maintenance dosing with Leqembi will prolong treatment benefits by targeting protofibrils, a toxic form of beta-amyloid.
The drugmaker emphasized plans to move further away from singular reliance on Keytruda while reporting solid sales growth in ...
Several new studies appear to confirm the test's potential to prevent overtreatment of melanoma patients while identifying those at high risk.
BMS third quarter revenues increased 8 percent to $11.90 billion, with its growth portfolio now making up half of total revenues.
NEW YORK – Akeso Biopharma on Wednesday said it dosed the first patient with PD-L1-positive advanced head and neck cancer in a Phase III trial, comparing the activity of its PD-1/VEGF bispecific ...
Based on early, interim data, Lexeo is already positioning its gene therapy as a potentially safer alternative than available anti-amyloid drugs.
Sales for Lumakras and Blincyto in particular soared during the third quarter as the firm's overall revenues climbed 23 percent year over year.
NEW YORK – Alloplex Biotherapeutics on Thursday said it will submit an investigational new drug application to the US Food and Drug Administration to begin a Phase II trial of its autologous ...
The drugmakers will explore the efficacy of Dato-DXd in combination with other drugs in PD-L1-expressing or EGFR-mutated NSCLC in these studies.